Iron Metabolism, Ferroptosis, and Anemia Management in Oncology and Chronic Disease
This research community investigates the biological mechanisms of iron regulation and the specific form of cell death known as ferroptosis, applying these findings to the treatment of cancer, the management of anemia, and the understanding of chronic conditions like heart failure and kidney disease.
The work centers on the dual role of iron in human health, ranging from the clinical management of deficiency and overload to its function in cellular signaling. A dominant strand of research explores ferroptosis, an iron-dependent form of cell death, and its role in tumor suppression and therapy resistance across breast, lung, and colorectal cancers. Concurrently, the community examines the efficacy of various iron therapies, including intravenous formulations like ferric carboxymaltose and iron sucrose, for treating anemia in patients with heart failure, kidney disease, and during pregnancy. These studies frequently utilize signaling pathway analysis and oxidative stress markers to understand how iron homeostasis influences cell survival and death.
The largest share of the community's output is found in iron research, accounting for 3.9% of all iron research, with 16,755 papers in this group. Oxygen and sulfur also feature prominently, each representing 0.5% of their respective element research.
The community comprises 31,594 papers, with the most frequent venues being Blood, the Journal of Biological Chemistry, and Signal Transduction and Targeted Therapy.
Recent work continues to focus on the intersection of ferroptosis and cancer therapy, including strategies to overcome treatment resistance in glioblastoma and the use of nanoparticles to induce cell death. Other recent studies examine iron delivery platforms for fortification and the role of ferroptosis in bone remodeling and osteoporosis.